465 related articles for article (PubMed ID: 30776797)
1. A Cost-Effectiveness Analysis of Vaccination for Prevention of Herpes Zoster and Related Complications: Input for National Recommendations.
Prosser LA; Harpaz R; Rose AM; Gebremariam A; Guo A; Ortega-Sanchez IR; Zhou F; Dooling K
Ann Intern Med; 2019 Mar; 170(6):380-388. PubMed ID: 30776797
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States who have been previously vaccinated with zoster vaccine live.
Curran D; Patterson BJ; Van Oorschot D; Buck PO; Carrico J; Hicks KA; Lee B; Yawn BP
Hum Vaccin Immunother; 2019; 15(4):765-771. PubMed ID: 30625011
[TBL] [Abstract][Full Text] [Related]
3. Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults.
McGirr A; Van Oorschot D; Widenmaier R; Stokes M; Ganz ML; Jung H; Varghese L; Curran D
Appl Health Econ Health Policy; 2019 Oct; 17(5):723-732. PubMed ID: 31250218
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of Recombinant Zoster Vaccine (RZV) and Varicella Vaccine Live (VVL) against herpes zoster and post-herpetic neuralgia among adults aged 65 and over in Japan.
Hoshi SL; Seposo X; Shono A; Okubo I; Kondo M
Vaccine; 2019 Jun; 37(27):3588-3597. PubMed ID: 31153691
[TBL] [Abstract][Full Text] [Related]
5. Cost-Effectiveness of Herpes Zoster Vaccine for Persons Aged 50 Years.
Le P; Rothberg MB
Ann Intern Med; 2015 Oct; 163(7):489-97. PubMed ID: 26344036
[TBL] [Abstract][Full Text] [Related]
6. Public health impact of herpes zoster vaccination on older adults in Hong Kong.
Chan PKS; Wong MCS; Chan M; Ching K; Giannelos N; Ng C
Hum Vaccin Immunother; 2023 Dec; 19(1):2176065. PubMed ID: 36854447
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of the recombinant zoster vaccine in the German population aged ≥60 years old.
Van Oorschot D; Anastassopoulou A; Poulsen Nautrup B; Varghese L; von Krempelhuber A; Neine M; Lorenc S; Curran D
Hum Vaccin Immunother; 2019; 15(1):34-44. PubMed ID: 30130448
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of the recombinant zoster vaccine (RZV) against herpes zoster: An updated critical review.
Giannelos N; Ng C; Curran D
Hum Vaccin Immunother; 2023 Dec; 19(1):2168952. PubMed ID: 36916240
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of an Adjuvanted Recombinant Zoster Vaccine in older adults in the United States.
Curran D; Patterson B; Varghese L; Van Oorschot D; Buck P; Carrico J; Hicks K; Lee B; Yawn B
Vaccine; 2018 Aug; 36(33):5037-5045. PubMed ID: 30017145
[TBL] [Abstract][Full Text] [Related]
10. Incremental clinical and economic impact of recombinant zoster vaccination: real-world data in a budget impact model.
Patterson BJ; Herring WL; Van Oorschot D; Curran D; Carrico J; Zhang Y; Ackerson BK; Bruxvoort K; Sy LS; Tseng HF
J Manag Care Spec Pharm; 2020 Dec; 26(12):1567-1575. PubMed ID: 33043821
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
Hornberger J; Robertus K
Ann Intern Med; 2006 Sep; 145(5):317-25. PubMed ID: 16954357
[TBL] [Abstract][Full Text] [Related]
12. Public health impact model estimating the impact of introducing an adjuvanted recombinant zoster vaccine into the UK universal mass vaccination programme.
van Oorschot DAM; Hunjan M; Bracke B; Lorenc S; Curran D; Starkie-Camejo H
BMJ Open; 2019 May; 9(5):e025553. PubMed ID: 31061027
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and cost-effectiveness of vaccination against herpes zoster in Canada: a modelling study.
Drolet M; Zhou Z; Sauvageau C; DeWals P; Gilca V; Amini R; Bénard É; Brisson M
CMAJ; 2019 Aug; 191(34):E932-E939. PubMed ID: 31451524
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness Analysis of Vaccination With Recombinant Zoster Vaccine Among Hematopoietic Cell Transplant Recipients and Persons With Other Immunocompromising Conditions Aged 19 to 49 Years.
Leidner AJ; Anderson TC; Hong K; Ortega-Sanchez IR; Guo A; Pike J; Prosser LA; Dooling KL
Value Health; 2023 Feb; 26(2):204-215. PubMed ID: 36243666
[TBL] [Abstract][Full Text] [Related]
15. Risk of Guillain-Barré Syndrome Following Recombinant Zoster Vaccine in Medicare Beneficiaries.
Goud R; Lufkin B; Duffy J; Whitaker B; Wong HL; Liao J; Lo AC; Parulekar S; Agger P; Anderson SA; Wernecke M; MaCurdy TE; Weintraub E; Kelman JA; Forshee RA
JAMA Intern Med; 2021 Dec; 181(12):1623-1630. PubMed ID: 34724025
[TBL] [Abstract][Full Text] [Related]
16. Public health impact of herpes zoster vaccination on older adults in Singapore: a modeling study.
Oh H; Tan C; Williams C; Giannelos N; Ng C
Hum Vaccin Immunother; 2024 Dec; 20(1):2348839. PubMed ID: 38804600
[TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness of Herpes Zoster Vaccination: A Systematic Review.
Chiyaka ET; Nghiem VT; Zhang L; Deshpande A; Mullen PD; Le P
Pharmacoeconomics; 2019 Feb; 37(2):169-200. PubMed ID: 30367401
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
Pellissier JM; Brisson M; Levin MJ
Vaccine; 2007 Nov; 25(49):8326-37. PubMed ID: 17980938
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of the Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults.
Le P; Rothberg MB
JAMA Intern Med; 2018 Feb; 178(2):248-258. PubMed ID: 29297049
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of vaccination of immunocompetent older adults against herpes zoster in the Netherlands: a comparison between the adjuvanted subunit and live-attenuated vaccines.
de Boer PT; van Lier A; de Melker H; van Wijck AJM; Wilschut JC; van Hoek AJ; Postma MJ
BMC Med; 2018 Dec; 16(1):228. PubMed ID: 30518427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
